title: Proteomic-based biosignatures in breast cancer classification and prediction of therapeutic response.
abstract: Protein-based markers that classify tumor subtypes and predict therapeutic response would be clinically useful in guiding patient treatment. We investigated the LC-MS/MS-identified protein biosignatures in 39 baseline breast cancer specimens including 28 HER2-positive and 11 triple-negative (TNBC) tumors. Twenty proteins were found to correctly classify all HER2 positive and 7 of the 11 TNBC tumors. Among them, galectin-3-binding protein and ALDH1A1 were found preferentially elevated in TNBC, whereas CK19, transferrin, transketolase, and thymosin β4 and β10 were elevated in HER2-positive cancers. In addition, several proteins such as enolase, vimentin, peroxiredoxin 5, Hsp 70, periostin precursor, RhoA, cathepsin D preproprotein, and annexin 1 were found to be associated with the tumor responses to treatment within each subtype. The MS-based proteomic findings appear promising in guiding tumor classification and predicting response. When sufficiently validated, some of these candidate protein markers could have great potential in improving breast cancer treatment.
authors: Gonda/UCLA Breast Cancer Research Laboratory, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, USA.
authors: Jianbo
authors: J
authors: He
authors: Stephen A
authors: SA
authors: Whelan
authors: Ming
authors: M
authors: Lu
authors: Dejun
authors: D
authors: Shen
authors: Debra U
authors: DU
authors: Chung
authors: Romaine E
authors: RE
authors: Saxton
authors: Kym F
authors: KF
authors: Faull
authors: Julian P
authors: JP
authors: Whitelegge
authors: Helena R
authors: HR
authors: Chang